Evidence map›Paper›PMID 41012540›Full record

ArticlePharmaceutics2025

A Pilot, Randomised, Placebo-Controlled, Double-Blind Trial of a Single Oral Dose of Ivermectin for Post-Exposure Prophylaxis of SARS-CoV-2.

Kylie M Wagstaff, Mark S Stein, Alan Herschtal, Jean-Jacques Rajter, Juliana Cepelowicz Rajter, Michele Sallaberger, Alexia Smileski, Amala Kanagalingam, David A Jans

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kylie M WagstaffBiomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Mark S SteinKnox Private Hospital, Wantirna, VIC 3152, Australia.
Alan HerschtalSchool of Public Health and Preventative Medicine, Monash University, Melbourne, VIC 3004, Australia.ORCID 0009-0004-2061-4787
Jean-Jacques RajterPulmonary and Sleep Consultants, 1001 South Andrews Ave, Fort Lauderdale, FL 33316, USA.
Juliana Cepelowicz RajterPulmonary and Sleep Consultants, 1001 South Andrews Ave, Fort Lauderdale, FL 33316, USA.
Michele SallabergerNeuroscience Trials Australia, 30 Royal Parade, Parkville, VIC 3052, Australia.
Alexia SmileskiNeuroscience Trials Australia, 30 Royal Parade, Parkville, VIC 3052, Australia.
Amala KanagalingamNeuroscience Trials Australia, 30 Royal Parade, Parkville, VIC 3052, Australia.
David A JansBiomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0001-5115-4745

Funding

Leona M. and Harry B. Helmsley Charitable Trust N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ivermectinpost-exposure prophylaxisrandomised controlled trialSARS-CoV-2

Identifiers

PMID41012540
PMCPMC12473430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.